Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of oral zasocitinib in active ulcerative colitis and Crohn's disease
CTR20253581Phase 2Active
- Sponsor
- Takeda
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zasocitinib in autoimmune colitis, Crohn's disease, sponsored by Takeda. Started May 2025; status: active.
02
Drugs
zasocitinib
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on CTR20253581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253581.